The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor
Open accessAbstract
Rifampicin, an important drug in the treatment of tuberculosis, is used extensively despite its broad effects on drug-drug interactions, creating serious problems. The clinical importance of such interactions includes autoinduction leading to suboptimal or failed treatment. The concomitantly administered effects of rifampicin on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by p-glycoprotein in the gastrointestinal tract and liver. This review paper summarises recent findings with emphases on the molecular mechanisms used to explain these broad drug-drug interactions. In general, rifampicin can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities. This pattern of action may explain many of the rifampicin inducing drug-drug interactions. However, effects through other mechanisms have also been reported and these make any explanation of such drug-drug interactions more complex.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,945
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., et al. (1993) · DNA and Cell Biology · doi:10.1089/dna.1993.12.1 · Cited by 1,655
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
Clinical importance of the cytochromes P450
Nebert, D. W., & Russell, D. W. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11203-7 · Cited by 1,414
Cytochromes P450: a success story.
Werck‐Reichhart, D., & Feyereisen, R. (2000) · Genome biology · doi:10.1186/gb-2000-1-6-reviews3003 · Cited by 1,004
SXR, a novel steroid and xenobioticsensing nuclear receptor
Blumberg, B., Sabbagh, W., Juguilon, H., Bolado, J., van Meter, C. M., Ong, E. S., & Evans, R. M. (1998) · Genes & Development · doi:10.1101/gad.12.20.3195 · Cited by 919
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Identification of a human nuclear receptor defines a new signaling pathway for CYP 3 A induction
Bertilsson, G., Heidrich, J., Svensson, K., Åsman, M., Jendeberg, L., Sydow-Bäckman, M., Ohlsson, R., Postlind, H., Blomquist, P., & Berkenstam, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12208 · Cited by 872
Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin
Geick, A., Eichelbaum, M., & Burk, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010173200 · Cited by 848
Human P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
The Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity
Watkins, R. E., Wisely, G. B., Moore, L. B., Collins, J. L., Lambert, M. H., Williams, S. P., Willson, T. M., Kliewer, S. A., & Redinbo, M. R. (2001) · Science · doi:10.1126/science.1060762 · Cited by 760
Waxman, D. J. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1351 · Cited by 753
Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400293200 · Cited by 705
Humanized xenobiotic response in mice expressing nuclear receptor SXR
Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brunt, E. M., Guzelian, P. S., & Evans, R. M. (2000) · Nature · doi:10.1038/35019116 · Cited by 660
Maglich, J. M., Stoltz, C. M., Goodwin, B., Hawkins-Brown, D., Moore, J. T., & Kliewer, S. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.638 · Cited by 654
Goodwin, B., Hodgson, E., & Liddle, C. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12400-5 · Cited by 646
Chen, W. S., Manova, K., Weinstein, D. C., Duncan, S. A., Plump, A. S., Prezioso, V. R., Bachvarova, R. F., & Darnell, J. E. (1994) · Genes & Development · doi:10.1101/gad.8.20.2466 · Cited by 552
Phenobarbital induction of cytochrome P-450 gene expression
Waxman, D. J., & Azaroff, L. (1992) · Biochemical Journal · doi:10.1042/bj2810577 · Cited by 532
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C., & Watkins, P. B. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116064 · Cited by 528
Schuetz, E. G., Beck, W. T., & Schuetz, J. D. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08713-9 · Cited by 494
Impact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Lee, A. J., Cai, M. X., Thomas, P. E., Conney, A. H., & Zhu, B. T. (2003) · Endocrinology · doi:10.1210/en.2003-0192 · Cited by 456
The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4
Tirona, R. G., Lee, W., Leake, B. F., Lan, L.-B., Cline, C. B., Lamba, V., Parviz, F., Duncan, S. A., Inoue, Y., Gonzalez, F. J., et al. (2003) · Nature Medicine · doi:10.1038/nm815 · Cited by 440
Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397
Sugatani, J., Kojima, H., Ueda, A., Kakizaki, S., Yoshinari, K., Gong, Q.-H., Owens, I. S., Negishi, M., & Sueyoshi, T. (2001) · Hepatology · doi:10.1053/jhep.2001.24172 · Cited by 381
Isoniazid-Associated Hepatitis in 114 Patients
Black, M., Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., & Epler, G. R. (1975) · Gastroenterology · doi:10.1016/s0016-5085(19)32568-5 · Cited by 370
Substrates of human hepatic cytochrome P450 3A4
Li, A. (1995) · Toxicology · doi:10.1016/0300-483x(95)03155-9 · Cited by 367
Xie, W., Yeuh, M.-F., Radominska-Pandya, A., Saini, S. P. S., Negishi, Y., Bottroff, B. S., Cabrera, G. Y., Tukey, R. H., & Evans, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0438010100 · Cited by 367
Xenobiotic-inducible Transcription of Cytochrome P450 Genes
Denison, M. S., & Whitlock, J. P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.31.18175 · Cited by 354
Watkins, P. B., Murray, S. A., Winkelman, L. G., Heuman, D. M., Wrighton, S. A., & Guzelian, P. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113933 · Cited by 345
Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials
Burman, W. J., Gallicano, K., & Peloquin, C. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140050-00002 · Cited by 337
Determination of drug metabolizing enzymes in needle biopsies of human liver
Schoene, B., Fleischmann, R. A., Remmer, H., & v. Oldershausen, H. F. (1972) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562499 · Cited by 328
Transcriptional Control of Intestinal Cytochrome P-4503A by 1α,25-Dihydroxy Vitamin D3
Thummel, K. E., Brimer, C., Yasuda, K., Thottassery, J., Senn, T., Lin, Y., Ishizuka, H., Kharasch, E., Schuetz, J., & Schuetz, E. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1399 · Cited by 325
Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s
Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Korzekwa, K. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90602-f · Cited by 324
Combalbert, J., Fabre, I., Fabre, G., Dalet, I., Derancourt, J., Cano, J. P., & Maurel, P. (1989) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08744-6 · Cited by 306
Rae, J. M., Johnson, M. D., Lippman, M. E., & Flockhart, D. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29202-8 · Cited by 306
Westphal, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109797 · Cited by 285
Overview of enzymes of drug metabolism
Meyer, U. A. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353473 · Cited by 279
Intervention Research in Rational Use of Drugs: A Review
Le Grand, A., Hogerzeil, H. V., & Haaijer-Ruskamp, F. M. (1999) · Health Policy and Planning · doi:10.1093/heapol/14.2.89 · Cited by 268
Role of P-Glycoprotein in Drug Disposition
Tanigawara, Y. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200002000-00029 · Cited by 261
von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M., & Kivistö, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.008 · Cited by 255
Transcriptional Regulation of the Human CYP3A4Gene by the Constitutive Androstane Receptor
Goodwin, B., Hodgson, E., D'Costa, D. J., Robertson, G. R., & Liddle, C. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.2.359 · Cited by 254
Tukey, R. H., & Strassburg, C. P. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12228-6 · Cited by 237
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
Baldwin, Clarke, & Chenery (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00030.x · Cited by 235
Rifampin and Rifabutin Drug Interactions: An Update
Finch, C. K., Chrisman, C. R., Baciewicz, A. M., & Self, T. H. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.9.985 · Cited by 233
Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor
Kliewer, S. A., & Willson, T. M. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30141-3 · Cited by 231
Rifampicin reduces effectiveness and bioavailability of prednisolone.
McAllister, W. A., Thompson, P. J., Al-Habet, S. M., & Rogers, H. J. (1983) · BMJ · doi:10.1136/bmj.286.6369.923 · Cited by 227
Chen, Y., Ferguson, S. S., Negishi, M., & Goldstein, J. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.058818 · Cited by 224
Jover, R. (2001) · Hepatology · doi:10.1053/jhep.2001.22176 · Cited by 216
Wang, H., Faucette, S., Sueyoshi, T., Moore, R., Ferguson, S., Negishi, M., & LeCluyse, E. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212482200 · Cited by 215
The effect of rifampin administration on the disposition of fexofenadine
Hamman, M. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113697 · Cited by 205
Update on Rifampin Drug Interactions
Baciewicz, A. M. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.147.3.565 · Cited by 202
Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis
Prince, M. I., Burt, A. D., & Jones, D. E. J. (2002) · Gut · doi:10.1136/gut.50.3.436 · Cited by 202
Hesse, L. M., He, P., Krishnaswamy, S., Hao, Q., Hogan, K., Moltke, L. L., Greenblatt, D. J., & Court, M. H. (2004) · Pharmacogenetics · doi:10.1097/00008571-200404000-00002 · Cited by 193
The Diagnosis and Therapy of Tuberculosis During the Past 100 Years
Mitchison, D. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1603oe · Cited by 185
Badawi, A. F., Cavalieri, E. L., & Rogan, E. G. (2001) · Metabolism · doi:10.1053/meta.2001.25592 · Cited by 184
REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS
Faucette, S. R., Wang, H., Hamilton, G. A., Jolley, S. L., Gilbert, D., Lindley, C., Yan, B., Negishi, M., & LeCluyse, E. L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.348 · Cited by 179
Yueh, M.-F., Huang, Y.-H., Hiller, A., Chen, S., Nguyen, N., & Tukey, R. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300645200 · Cited by 177
Maurer, G. (1985) · PubMed · Cited by 172
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
Kyrklund, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111414 · Cited by 163
Cummins, C. L., Salphati, L., Reid, M. J., & Benet, L. Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.044719 · Cited by 161
Bolton, A. E., Peng, B., Hubert, M., Krebs-Brown, A., Capdeville, R., Keller, U., & Seiberling, M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0722-9 · Cited by 160
AN ASSESSMENT OF UDP-GLUCURONOSYLTRANSFERASE INDUCTION USING PRIMARY HUMAN HEPATOCYTES
Soars, M. G., Petullo, D. M., Eckstein, J. A., Kasper, S. C., & Wrighton, S. A. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.1.140 · Cited by 152
Liddle, C., Goodwin, B. J., George, J., Tapner, M. J., & Farrell, G. C. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4877 · Cited by 142
Pharmacokinetics of oral and intravenous rifampicin during chronic administration
Loos, U., Musch, E., Jensen, J. C., Mikus, G., Schwabe, H. K., & Eichelbaum, M. F. (1985) · Journal of Molecular Medicine · doi:10.1007/bf01733779 · Cited by 141
Kamiya, A., Inoue, Y., & Gonzalez, F. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50212 · Cited by 140
Metabolism of 17 α-ethynylestradiol in humans
Guengerich, F. P. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90431-p · Cited by 139
The effects of fruit juices on drug disposition: a new model for drug interactions
Dresser, G. K., & Bailey, D. G. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.2.x · Cited by 139
Barwick, J. L., Quattrochi, L. C., Mills, A. S., Potenza, C., Tukey, R. H., & Guzelian, P. S. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09115-1 · Cited by 134
The interaction of diltiazem with simvastatin
Mousa, O., Brater, D. C., Sundblad, K. J., & Hall, S. D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104609 · Cited by 131
Gießmann, T., Modeß, C., Hecker, U., Zschiesche, M., Dazert, P., Kunert‐Keil, C., Warzok, R., Engel, G., Weitschies, W., Cascorbi, I., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.004 · Cited by 130
Sugatani, J., Yamakawa, K., Tonda, E., Nishitani, S., Yoshinari, K., Degawa, M., Abe, I., Noguchi, H., & Miwa, M. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.11.002 · Cited by 107
Clinically Significant Interactions with Drugs Used in the Treatment of Tuberculosis
Ww, Y. (2002) · Drug Safety · doi:10.2165/00002018-200225020-00005 · Cited by 107
Study of Oxidative-Stress in Isoniazid-Rifampicin Induced Hepatic Injury in Young Rats
Sodhi, C. P., Rana, S., Mehta, S. K., Vaiphei, K., Attari, S. S., & Mehta, S. K. (1997) · Drug and Chemical Toxicology · doi:10.3109/01480549709003881 · Cited by 105
Schmiedlin‐Ren, P., Thummel, K. E., Fisher, J. M., Paine, M. F., & Watkins, P. B. (2001) · PubMed · Cited by 102
Effect of Rifampin on the Pharmacokinetics of Rosiglitazone in Healthy Subjects
Park, J. Y., Kim, K., Kang, M., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.003 · Cited by 98
INTERACTION OF RIFAMPICIN TREATMENT WITH PHARMACOKINETICS AND METABOLISM OF ETHINYLOESTRADIOL IN MAN
Bolt, H. M., Bolt, M., & Kappus, H. (1977) · European Journal of Endocrinology · doi:10.1530/acta.0.0850189 · Cited by 95
Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes
Glaeser, H., Drescher, S., Eichelbaum, M. F., & Fromm, M. F. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02265.x · Cited by 94
Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells
Zhao, J. Y., Ikeguchi, M., Eckersberg, T., & Kuo, M. T. (1993) · Endocrinology · doi:10.1210/en.133.2.521 · Cited by 93
Lin, J. H., Chiba, M., Chen, I., Nishime, J. A., Deluna, F. A., Yamazaki, M., & Lin, Y. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15044-1 · Cited by 93
Benedetti, M. S., & Dostert, P. (1994) · Environmental Health Perspectives · doi:10.1289/ehp.94102s9101 · Cited by 92
Liddle, C. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2411 · Cited by 91
Cançado, E. L. R., Leitão, R. M. C., Carrilho, F. J., & Laudanna, A. A. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00472.x · Cited by 90
The effect of rifampicin oh the pharmacokinetics of ethynylestradiol in women
Back, D. J., Breckenridge, A., Crawford, F. E., Hall, J. M., MacIver, M., Orme, M. L., Rowe, P. H., Smith, E., & Watts, M. J. (1980) · Contraception · doi:10.1016/0010-7824(80)90125-0 · Cited by 87
TRANSCRIPTIONAL ACTIVATION OF CYTOCHROME P450 GENES BY DIFFERENT CLASSES OF CHEMICAL INDUCERS
Dogra, S. C., Whitelaw, M. L., & May, B. K. (1998) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1998.tb02135.x · Cited by 86
Lin, J. H., Chiba, M., Chen, I., et al. (1999) · PubMed · Cited by 83
Pharmacokinetics of Digoxin and Main Metabolites/Derivatives in Healthy Humans
Hinderling, P. H., & Hartmann, D. (1991) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199109000-00001 · Cited by 79
El-Sankary, W., Bombail, V., Gibson, G. G., & Plant, N. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.9.1029 · Cited by 68
Johnson, B. M., Chen, W., Borchardt, R. T., Charman, W. N., & Porter, C. J. H. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045328 · Cited by 68
Dilger, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.106872 · Cited by 66
Increased Plasma Rifabutin Levels with Concomitant Fluconazole Therapy in HIV-Infected Patients
Trapnell, C. B., Narang, P. K., Li, R., & Lavelle, J. P. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-6-199603150-00006 · Cited by 62
Difficulties in Anticoagulation Management during Coadministration of Warfarin and Rifampin
Lee, C. R., & Thrasher, K. A. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.15.1240.33897 · Cited by 61
Lacarelle, B., Rahmani, R., de Sousa, G., Durand, A., Placidi, M., & Cano, J. P. (1991) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1991.tb00746.x · Cited by 61
Induction of Multidrug Resistance-1 and Cytochrome P450 mRNAs in Human Mononuclear Cells by Rifampin
Asghar, A., Gorski, J. C., HAEHNERDANIELS, B., & Hall, S. D. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.1.20 · Cited by 61
[The simultaneous use of rifampicin and other antitubercular agents with oral contraceptives].
Reimers, D., & Jezek, A. (1971) · PubMed · Cited by 58
IN VIVO INDUCTION OF HUMAN CYTOCHROME P450 ENZYMES EXPRESSED IN CHIMERIC MICE WITH HUMANIZED LIVER
Katoh, M., Matsui, T., Nakajima, M., Tateno, C., Soeno, Y., Horie, T., Iwasaki, K., Yoshizato, K., & Yokoi, T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002600 · Cited by 57
Song, X., Xie, M., Zhang, H., Li, Y., Sachdeva, K., & Yan, B. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.1.35 · Cited by 54
Induction of propranolol metabolism by rifampicin.
Herman, R., Nakamura, K., Wilkinson, G., et al. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb02218.x · Cited by 52
Zilly, W., Breimer, D. D., & Richter, E. A. (1977) · European Journal of Clinical Pharmacology · doi:10.1007/bf00607679 · Cited by 51
Apseloff, G., Foulds, G. H., LaBoy‐Goral, L., Willavize, S. A., & Vincent, J. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb00017.x · Cited by 43
Interaction of Rifampin and Warfarin
Self, T. H., & Mann, R. B. (1975) · CHEST Journal · doi:10.1378/chest.67.4.490 · Cited by 39
Mecanismos de hepatotoxicidade
Bertolami, M. C. (2005) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2005002400007 · Cited by 39
Jordan, M. K., Polis, M. A., Kelly, G., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2170-2172.2000 · Cited by 37
Bolt, H. M. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033432 · Cited by 36
Induction of CYP3A4 by 1α,25-dyhydroxyvitamin D3 in HepG2 cells
Elizondo, G., & Medina‐Díaz, I. M. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00262-5 · Cited by 35
Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis
Kim, Y. H., Kim, Y. H., Yoon, Y. R., et al. (1998) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)01139-7 · Cited by 28
Hesse, L. M., Sakai, Y., Vishnuvardhan, D., et al. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021657 · Cited by 28
EFFECTS OF AVASIMIBE ON CYTOCHROME P450 2C9 EXPRESSION IN VITRO AND IN VIVO
Sahi, J., Stern, R. H., Milad, M. A., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000208 · Cited by 27
Karan, R. S., Bhargava, V. K., & Garg, S. K. (1999) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(98)00127-5 · Cited by 22
Update on rifampin drug interactions, III
Strayhorn, V. A. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.21.2453 · Cited by 14
Effects of Rifampin on Cyclosporine Disposition in Kidney Recipients with Tuberculosis
Shon, J., Yoon, Y., Kim, K., et al. (2000) · Journal of Korean Society for Clinical Pharmacology and Therapeutics · doi:10.12793/jkscpt.2000.8.1.91 · Cited by 7
Cited by
Diacon, A. H., Dawson, R., von Groote-Bidlingmaier, F., Symons, G., Venter, A., Donald, P. R., van Niekerk, C., Everitt, D., Winter, H., Becker, P., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61080-0 · Cited by 435
Metadata
- Authors
- Chen, J., & Raymond, K.
- Venue
- Annals of Clinical Microbiology and Antimicrobials
- Published
- 2006-01
- Volume
- 5
- Issue
- 1
- Pages
- 3-3
- ISSN
- 1476-0711 (ISSN-L)
- OpenAlex
- W2105634155
- Cited by
- 296
- References
- 116
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.